Stockscreener 앱 받기
2.575
6.70%
-0.185
전일 마감가:
$2.76
열려 있는:
$2.7289
하루 거래량:
30,961
Relative Volume:
0.94
시가총액:
$38.89M
수익:
-
순이익/손실:
$-16.26M
주가수익비율:
-2.1796
EPS:
-1.1814
순현금흐름:
$-13.50M
1주 성능:
-0.96%
1개월 성능:
+36.97%
6개월 성능:
-45.79%
1년 성능:
-46.02%
1일 변동 폭
$2.50
$2.81
1주일 범위
$2.36
$3.1663
52주 변동 폭
$1.50
$5.94
인텐시티 테라퓨틱스 Stock (INTS) Company Profile
명칭
Intensity Therapeutics Inc
전화
203-221-7381
주소
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
INTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
2.575 | 38.89M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
인텐시티 테라퓨틱스 주식(INTS)의 최신 뉴스
Soft Tissue Sarcoma Market Poised for Significant Growth from - openPR
Soft Tissue Sarcoma Pipeline Review 2024: Clinical Trials - openPR
Alliance Global Partners Initiates Coverage of Intensity Therapeutics (INTS) with Buy Recommendation - MSN
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 - PR Newswire
Avoiding Isolation By Volunteering Offers Mental Health Benefits to Seniors - 69News WFMZ-TV
Retrospective Analysis of Dosimetric Comparison Between Intensity-Modulated Radiation Therapy and Volumetric-Modulated Arc Therapy in Patients With Esophageal Cancer - Cureus
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Intensity Therapeutics stock hits 52-week low at $1.73 By Investing.com - Investing.com Australia
Intensity Therapeutics stock hits 52-week low at $1.73 - Investing.com
Internal Radiation Therapy - Market.us
Myelodysplastic Syndrome (MDS) Drugs Market Trends and Sales Forecast to 2030: Total Revenues to Reach US$4.1 Billion Worldwide, with Immunomodulatory Drugs Dominating Shares - GlobeNewswire
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 By Investing.com - Investing.com Australia
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 - Investing.com
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List - Yahoo Finance
Intensity Therapeutics reports positive results of INT230-6 in breast cancer - Yahoo Finance
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Yahoo Finance
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - Insider Monkey
Clinical Trials News Live Feed - StockTitan
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - Yahoo Finance
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Brea - Yahoo Finance
Candel Therapeutics Prostate Cancer Therapy Shows Promise - Yahoo Finance
Candel Therapeutics stock up 172% after Phase III prostate cancer success - Yahoo Finance
Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial - Yahoo Finance
Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - The Eastern Progress Online
Intensity Therapeutics stock hits 52-week low at $2.46 By Investing.com - Investing.com Canada
Intensity Therapeutics stock hits 52-week low at $2.46 - Investing.com
The Benchmark Company Announces Upcoming Discovery One-on-One Investor Conference - The Manila Times
Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit - Yahoo Finance
Costco to end book sales in hundreds of stores. Will Michigan stores see changes? - Yahoo Finance
TG Therapeutics to Participate in the Evercore HealthCONx Conference - Yahoo Finance
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Intensity Therapeutics Selected for Oral Podium Presentation in - GuruFocus.com
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Fundus Camera Market Global Forecasts and Company Analysis 2025-2033, Profiles of Carl Zeiss Medites, Topcon Medical Systems, Merit Medical Systems, NIDEK, and Revenio Group - Yahoo Finance
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO - AlphaStreet
Intensity Therapeutics secures $3 million in stock offering By Investing.com - Investing.com South Africa
Medical supplies giant Medline reportedly eyeing $5B IPO in 2025 - MSN
Intensity Therapeutics secures $3 million in stock offering - Investing.com India
Shelton-based Intensity Therapeutics gains $3M investment - Hartford Business Journal
H2G Green Limited Launches Major Rights Issue - MSN
Intensity Therapeutics Raises $3M Through Stock Offering & Warrant Placement - StockTitan
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial - Yahoo Finance
Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease - Yahoo Finance
Intensity reports promising sarcoma treatment results - Investing.com
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at - StreetInsider.com
Intensity reports promising sarcoma treatment results By Investing.com - Investing.com UK
Intensity Therapeutics' Cancer Drug Triples Survival Time in Phase 1/2 Sarcoma Trial | INTS Stock News - StockTitan
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Me - PR Newswire
인텐시티 테라퓨틱스 (INTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):